Efalizumab in the Treatment of Scalp, Palmoplantar and Nail Psoriasis: Results of a 24-Week Latin American Study-Reference-Cited by-同舟云学术

Efalizumab in the Treatment of Scalp, Palmoplantar and Nail Psoriasis: Results of a 24-Week Latin American Study

Published:2010-03 Issue:1 Volume:3 Page:1-8
ISSN:1753-5174
Container-title:Archives of Drug Information
language:en
Short-container-title:

Author:

Takahashi María Denise,Chouela Edgardo Néstor,Dorantes Gladys Leon,Roselino Ana Maria,Santamaria Jesùs,Allevato Miguel Angel,Cestari Tania,de Aillaud Maria Eugenia Manzanera,Stengel Fernando Miguel,Licu Daiana

Publisher

Wiley

Subject

Pharmacology (medical),Complementary and alternative medicine,General Pharmacology, Toxicology and Pharmaceutics

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1753-5174.2009.00025.x/fullpdf

Reference42 articles.

1. The immunologic basis for the treatment of psoriasis with new biologic agents;Krueger;J Am Acad Dermatol,2002

2. Treatment of psoriasis;Greaves;N Engl J Med,1995

3. Psoriasis and psoriatic arthritis: Immunological aspects and therapeutic guidelines;Griffiths;Clin Exp Rheumatol,2006

4. Psoriasis: Epidemiology, clinical features, and quality of life;Langley;Ann Rheum Dis,2005

5. Problem sites: Scalp, palm and sole, and nail;Larko;Dermatol Clin,1995

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review;American Journal of Clinical Dermatology;2023-05-20

2. Cost‐efficacy and pharmacoeconomics of scalp lesions of psoriatic patients in current Japanese health‐care insurance system;The Journal of Dermatology;2021-04-02

3. Outcome Measures in Psoriasis and Atopic Eczema;Biologic and Systemic Agents in Dermatology;2017-09-30

4. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis;Journal of the American Academy of Dermatology;2016-07

5. T-Cell Targeted Therapy: Alefacept and Efalizumab;Advances in Psoriasis;2014